ADVERTISEMENT
Shilpa Medicare Gets 'Buy' Rating As Systematix Initiates Coverage, Sets Target Price Of Rs 857
The brokerage believe Shilpa Medicare’s differentiated / CRAMS portfolio would help the company to deliver high-teen revenue growth and disproportionate profit expansion.
14 Feb 2025, 03:43 PM IST 
Shilpa Medicare’s recent history of successful approvals validate its capabilities in successfully executing and manufacturing difficult-to-develop and complex products
(image company website)
Shilpa Medicare is an research and development-driven formulation and active pharma ingredient-manufacturing company that focuses on complex /differentiated opportunities. Shilpa Medicare has built multiple R&D /manufacturing platforms that provide it access to large growing markets – biosimilars, peptides, ready to use injectables, orally dissolvable films, transdermal patches, and high-potency APIs.
